Cargando…
PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis
BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) belongs to an intracellular invertase or decarboxylase and is an independent risk factor for atherosclerosis (AS). This study aimed to investigate the therapeutic potential of the PCSK9 inhibitor, inclisiran, and its underlying mechan...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761140/ https://www.ncbi.nlm.nih.gov/pubmed/36544639 http://dx.doi.org/10.21037/atm-22-4652 |
_version_ | 1784852643191980032 |
---|---|
author | Kong, Ni Xu, Qin Cui, Wei Feng, Xiaoying Gao, Huijie |
author_facet | Kong, Ni Xu, Qin Cui, Wei Feng, Xiaoying Gao, Huijie |
author_sort | Kong, Ni |
collection | PubMed |
description | BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) belongs to an intracellular invertase or decarboxylase and is an independent risk factor for atherosclerosis (AS). This study aimed to investigate the therapeutic potential of the PCSK9 inhibitor, inclisiran, and its underlying mechanism in AS. METHODS: ApoE(-/-) mice were fed with a high-fat diet (HFD) and intraperitoneally injected with 1, 5, or 10 mg/kg inclisiran. Low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglyceride (TG), and high-density lipoprotein cholesterol (HDL-C) levels were determined using commercially available kits. Oil Red O staining was applied to detect the aortic plaque area and oil formation. Human umbilical vein endothelial cells (HUVECs) were treated with oxidized low-density lipoprotein (ox-LDL) to induce cell injuries. Cell death was determined using a Hoechst 33342/propidium iodide (PI) dual-staining assay. Cytotoxicity was measured by lactate dehydrogenase (LDH) activity analysis. Quantitative real-time polymerase chain reaction (qRT-PCR) and western blot analyses were performed to examine the pyroptosis-related factors. RESULTS: Inclisiran inhibited the levels of LDL-C, TC, and TG, but increased the HDL-C level in the AS animal model. It also significantly inhibited plaque and oil droplet formation in a dose-dependent manner. Moreover, inclisiran markedly inhibited pyroptosis, as evidenced by the decreased levels of cleaved-caspase-1, NOD-like receptor family pyrin domain containing 3 (NLRP3), apoptosis-associated speck-like protein containing a caspase-1 recruitment domain (ASC), gasdermin-D (GSDMD)-N, interleukin (IL)-1β, and IL-18. Furthermore, inclisiran substantially inhibited cell death and cytotoxicity induced by ox-LDL in HUVECs. CONCLUSIONS: Inclisiran exerted an anti-atherosclerotic effect by inhibiting pyroptosis. This study provides a theoretical basis for the therapeutic potential of inclisiran in AS. |
format | Online Article Text |
id | pubmed-9761140 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-97611402022-12-20 PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis Kong, Ni Xu, Qin Cui, Wei Feng, Xiaoying Gao, Huijie Ann Transl Med Original Article BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) belongs to an intracellular invertase or decarboxylase and is an independent risk factor for atherosclerosis (AS). This study aimed to investigate the therapeutic potential of the PCSK9 inhibitor, inclisiran, and its underlying mechanism in AS. METHODS: ApoE(-/-) mice were fed with a high-fat diet (HFD) and intraperitoneally injected with 1, 5, or 10 mg/kg inclisiran. Low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglyceride (TG), and high-density lipoprotein cholesterol (HDL-C) levels were determined using commercially available kits. Oil Red O staining was applied to detect the aortic plaque area and oil formation. Human umbilical vein endothelial cells (HUVECs) were treated with oxidized low-density lipoprotein (ox-LDL) to induce cell injuries. Cell death was determined using a Hoechst 33342/propidium iodide (PI) dual-staining assay. Cytotoxicity was measured by lactate dehydrogenase (LDH) activity analysis. Quantitative real-time polymerase chain reaction (qRT-PCR) and western blot analyses were performed to examine the pyroptosis-related factors. RESULTS: Inclisiran inhibited the levels of LDL-C, TC, and TG, but increased the HDL-C level in the AS animal model. It also significantly inhibited plaque and oil droplet formation in a dose-dependent manner. Moreover, inclisiran markedly inhibited pyroptosis, as evidenced by the decreased levels of cleaved-caspase-1, NOD-like receptor family pyrin domain containing 3 (NLRP3), apoptosis-associated speck-like protein containing a caspase-1 recruitment domain (ASC), gasdermin-D (GSDMD)-N, interleukin (IL)-1β, and IL-18. Furthermore, inclisiran substantially inhibited cell death and cytotoxicity induced by ox-LDL in HUVECs. CONCLUSIONS: Inclisiran exerted an anti-atherosclerotic effect by inhibiting pyroptosis. This study provides a theoretical basis for the therapeutic potential of inclisiran in AS. AME Publishing Company 2022-11 /pmc/articles/PMC9761140/ /pubmed/36544639 http://dx.doi.org/10.21037/atm-22-4652 Text en 2022 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Kong, Ni Xu, Qin Cui, Wei Feng, Xiaoying Gao, Huijie PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis |
title | PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis |
title_full | PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis |
title_fullStr | PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis |
title_full_unstemmed | PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis |
title_short | PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis |
title_sort | pcsk9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761140/ https://www.ncbi.nlm.nih.gov/pubmed/36544639 http://dx.doi.org/10.21037/atm-22-4652 |
work_keys_str_mv | AT kongni pcsk9inhibitorinclisiranfortreatingatherosclerosisviaregulationofendothelialcellpyroptosis AT xuqin pcsk9inhibitorinclisiranfortreatingatherosclerosisviaregulationofendothelialcellpyroptosis AT cuiwei pcsk9inhibitorinclisiranfortreatingatherosclerosisviaregulationofendothelialcellpyroptosis AT fengxiaoying pcsk9inhibitorinclisiranfortreatingatherosclerosisviaregulationofendothelialcellpyroptosis AT gaohuijie pcsk9inhibitorinclisiranfortreatingatherosclerosisviaregulationofendothelialcellpyroptosis |